Safety, immunogenicity, efficacy, and acceptability of COVID-19 vaccination in people with multiple sclerosis: a narrative review
Author:
Publisher
Medknow
Subject
Developmental Neuroscience
Reference62 articles.
1. Achiron A, Dolev M, Menascu S, Zohar DN, Dreyer-Alster S, Miron S, Shirbint E, Magalashvili D, Flechter S, Givon U, Guber D, Stern Y, Polliack M, Falb R, Gurevich M (2021) COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021. Mult Scler J 27:864-870.
2. Achiron A, Mandel M, Dreyer-Alster S, Harari G,Dolev M, Menascu S, Magalashvili D, Flechter S, Givon U, Guber D, Sonis P, Zilkha-Falb R, Gurevich M (2021) Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study. J Neuroimmunol 361:577746 24.
3. Achtnichts L, Jakopp B, Oberle M, Nedeltchev K, Fux CA, Sellner J, Findling O (2021) Humoral immune response after the third SARS-CoV-2 mRNA vaccination in CD20 depleted people with multiple sclerosis. Vaccines 9:1470.
4. Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, Rezk A, Patterson KR, Espinoza DA, Kadri JC, Markowitz DM, Markowitz C, Mexhitaj I, Jacobs D, Babb A, Betts MR, Prak E, Weiskopf D, Grifoni A, Lundgreen KA, et al. (2021) Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med 27:1990-2001.
5. Arora S, Grover V, Saluja P, Algarni YA, Saquib SA, Asif SM, Batra K, Alshahrani MY, Das G, Jain R, Ohri A (2022) Literature review of omicron: a grim reality amidst COVID-19. Microorganisms 10:451.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Treatment cost assessment for COVID-19 inpatients in Shenzhen, China 2020–2021: facts and suggestions;Frontiers in Public Health;2023-05-04
2. A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies;Journal of Neurology;2023-03-18
3. Immune response to COVID-19 vaccines in patients with multiple sclerosis treated with disease-modifying therapies;Neurologia i Neurochirurgia Polska;2023-02-28
4. A Review Pertaining to SARS-CoV-2 and Autoimmune Diseases: What Is the Connection?;Life;2022-11-18
5. The Concomitant Use o f Melatonin and Bebtelovimab as a Treatment Strategy for Omicron and Future Variants of Concern;International Journal of Pharmaceutical Research And Allied Sciences;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3